CONSORT-Independent Prognostic Value of Asphericity of Pretherapeutic F-18 FDG Uptake by Primary Tumors in Patients with Breast Cancer

Overview

Journal Medicine (Baltimore)

Specialty General Medicine

Date 2017 Nov 18

PMID 29145250

Citations 3

Authors

Ji-Hoon Jung

Seung Hyun Son

Do-Hoon Kim

Jeeyeon Lee

Shin Young Jeong

Sang-Woo Lee

Ho Yong Park

Jaetae Lee

Byeong-Cheol Ahn

Affiliations

Soon will be listed here.

Abstract

Background: The aim of this study was to evaluate the prognostic implication of asphericity (ASP); spatial irregularity; of pretherapeutic F 2-deoxy-2-fluoro-D-glucose (F FDG) tumor uptake in patients with invasive ductal carcinoma (IDC) of the breast.

Methods: One hundred thirty-one female IDC patients (mean age = 48.1 ± 10.4 years), with pathological tumor size greater than 2 cm were retrospectively evaluated using F FDG positron emission tomography/computed tomography (PET/CT). ASP of F FDG distribution was calculated on the basis of the deviation of the tumor shape from spherical symmetry. Progression-free survival (PFS) was predicted on the basis of the univariate and multivariate analyses of the measured clinicopathologic factors and metabolic PET parameters [maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV), and total lesion glycolysis (TLG)].

Results: The PFS rate among the 131 patients was 90.1%. The mean follow-up time was 50 months for the entire study cohort and 26 months for the patients with recurrent disease. It is evident from the univariate analysis that N stage, hormonal receptor (Estrogen, ER/Progesterone, PR) status, MTV (≤4.2 mL), and ASP (≤15.1%) affected the PFS. Hazard ratios (HRs) estimated from the multivariate Cox regression analysis show that N stage (HR = 17.6), ASP (HR = 11.9), and hormonal receptor status (HR = 6.9) were independent prognostic factors in predicting PFS. In the subgroup of patients with lymph node metastasis, ASP (HR = 10.9) and hormonal receptor status (HR = 9.1) were independent prognostic factors for PFS.

Conclusion: ASP of F FDG uptake is an independent predictor of outcome in IDC patients, and can be used for prognostic stratification.

Citing Articles

Asphericity derived from [F]FDG PET as a new prognostic parameter in cervical cancer patients.

Cegla P, Hofheinz F, Burchardt E, Czepczynski R, Kubiak A, van den Hoff J Sci Rep. 2023; 13(1):8423.

PMID: 37225735 PMC: 10209105. DOI: 10.1038/s41598-023-35191-8.

Radiomics analysis of pre-treatment [F]FDG PET/CT for patients with metastatic colorectal cancer undergoing palliative systemic treatment.

van Helden E, Vacher Y, van Wieringen W, van Velden F, Verheul H, Hoekstra O Eur J Nucl Med Mol Imaging. 2018; 45(13):2307-2317.

PMID: 30094460 PMC: 6208805. DOI: 10.1007/s00259-018-4100-6.

functions as a tumor suppressor and regulates migration and invasion in breast cancer.

Bhandari A, Xia E, Zhou Y, Guan Y, Xiang J, Kong L Cancer Manag Res. 2018; 10:969-976.

PMID: 29760566 PMC: 5937492. DOI: 10.2147/CMAR.S160379.

References

Lee C, Gold L, Nelson H, Chou R, Ramsey S, Sullivan S . Comparative effectiveness of imaging modalities to determine metastatic breast cancer treatment response. Breast. 2014; 24(1):3-11. DOI: 10.1016/j.breast.2014.11.009. View

Groheux D, Hatt M, Hindie E, Giacchetti S, de Cremoux P, Lehmann-Che J . Estrogen receptor-positive/human epidermal growth factor receptor 2-negative breast tumors: early prediction of chemosensitivity with (18)F-fluorodeoxyglucose positron emission tomography/computed tomography during neoadjuvant chemotherapy. Cancer. 2013; 119(11):1960-8. DOI: 10.1002/cncr.28020. View

Hatt M, Majdoub M, Vallieres M, Tixier F, Rest C, Groheux D . 18F-FDG PET uptake characterization through texture analysis: investigating the complementary nature of heterogeneity and functional tumor volume in a multi-cancer site patient cohort. J Nucl Med. 2014; 56(1):38-44. DOI: 10.2967/jnumed.114.144055. View

Park S, Lee E, Rhee S, Cho J, Choi S, Lee S . Correlation between Semi-Quantitative (18)F-FDG PET/CT Parameters and Ki-67 Expression in Small Cell Lung Cancer. Nucl Med Mol Imaging. 2016; 50(1):24-30. PMC: 4762859. DOI: 10.1007/s13139-015-0363-z. View

Kim C, Jeong S, Chong G, Son S, Jung J, Kim D . Quantitative metabolic parameters measured on F-18 FDG PET/CT predict survival after relapse in patients with relapsed epithelial ovarian cancer. Gynecol Oncol. 2015; 136(3):498-504. DOI: 10.1016/j.ygyno.2014.12.032. View

Hofheinz F, Lougovski A, Zophel K, Hentschel M, Steffen I, Apostolova I . Increased evidence for the prognostic value of primary tumor asphericity in pretherapeutic FDG PET for risk stratification in patients with head and neck cancer. Eur J Nucl Med Mol Imaging. 2014; 42(3):429-37. DOI: 10.1007/s00259-014-2953-x. View

Apostolova I, Rogasch J, Buchert R, Wertzel H, Achenbach H, Schreiber J . Quantitative assessment of the asphericity of pretherapeutic FDG uptake as an independent predictor of outcome in NSCLC. BMC Cancer. 2014; 14:896. PMC: 4265451. DOI: 10.1186/1471-2407-14-896. View

Kim J, Yoo S, Kang S, Cho S, Oh J, Chong A . Prognostic Significance of Metabolic Tumor Volume Measured by (18)F-FDG PET/CT in Operable Primary Breast Cancer. Nucl Med Mol Imaging. 2014; 46(4):278-85. PMC: 4043062. DOI: 10.1007/s13139-012-0161-9. View

Fitzmaurice C, Dicker D, Pain A, Hamavid H, Moradi-Lakeh M, MacIntyre M . The Global Burden of Cancer 2013. JAMA Oncol. 2015; 1(4):505-27. PMC: 4500822. DOI: 10.1001/jamaoncol.2015.0735. View

10.

Cheng N, Fang Y, Lee L, Chang J, Tsan D, Ng S . Zone-size nonuniformity of 18F-FDG PET regional textural features predicts survival in patients with oropharyngeal cancer. Eur J Nucl Med Mol Imaging. 2014; 42(3):419-28. DOI: 10.1007/s00259-014-2933-1. View

11.

Song B, Lee S, Jeong S, Chae Y, Lee W, Ahn B . 18F-FDG uptake by metastatic axillary lymph nodes on pretreatment PET/CT as a prognostic factor for recurrence in patients with invasive ductal breast cancer. J Nucl Med. 2012; 53(9):1337-44. DOI: 10.2967/jnumed.111.098640. View

12.

Tan M, Yu D . Molecular mechanisms of erbB2-mediated breast cancer chemoresistance. Adv Exp Med Biol. 2007; 608:119-29. DOI: 10.1007/978-0-387-74039-3_9. View

13.

Wolff A, Hammond M, Schwartz J, Hagerty K, Allred D, Cote R . American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2006; 25(1):118-45. DOI: 10.1200/JCO.2006.09.2775. View

14.

Ahn S, Park J, Lee H, Lee H, Jeon T, Han K . Standardized uptake value of ¹⁸F-fluorodeoxyglucose positron emission tomography for prediction of tumor recurrence in breast cancer beyond tumor burden. Breast Cancer Res. 2015; 16(6):502. PMC: 4308858. DOI: 10.1186/s13058-014-0502-y. View

15.

Groheux D, Giacchetti S, Moretti J, Porcher R, Espie M, Lehmann-Che J . Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer. Eur J Nucl Med Mol Imaging. 2010; 38(3):426-35. DOI: 10.1007/s00259-010-1640-9. View

16.

Demicheli R, Abbattista A, Miceli R, Valagussa P, Bonadonna G . Time distribution of the recurrence risk for breast cancer patients undergoing mastectomy: further support about the concept of tumor dormancy. Breast Cancer Res Treat. 1996; 41(2):177-85. DOI: 10.1007/BF01807163. View

17.

Park J, Chang K, Seo Y, Byun B, Choi J, Moon H . Tumor SUVmax Normalized to Liver Uptake on (18)F-FDG PET/CT Predicts the Pathologic Complete Response After Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer. Nucl Med Mol Imaging. 2015; 48(4):295-302. PMC: 4571668. DOI: 10.1007/s13139-014-0289-x. View

18.

Fisher B, Bauer M, Wickerham D, Redmond C, Fisher E, CRUZ A . Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. An NSABP update. Cancer. 1983; 52(9):1551-7. DOI: 10.1002/1097-0142(19831101)52:9<1551::aid-cncr2820520902>3.0.co;2-3. View

19.

Beggs A, Hain S, Curran K, ODoherty M . FDG-PET as a "metabolic biopsy" tool in non-lung lesions with indeterminate biopsy. Eur J Nucl Med Mol Imaging. 2002; 29(4):542-6. DOI: 10.1007/s00259-001-0736-7. View

20.

Tixier F, Hatt M, Valla C, Fleury V, Lamour C, Ezzouhri S . Visual versus quantitative assessment of intratumor 18F-FDG PET uptake heterogeneity: prognostic value in non-small cell lung cancer. J Nucl Med. 2014; 55(8):1235-41. DOI: 10.2967/jnumed.113.133389. View